Number of shares and voting rights of Innate Pharma as at July 17, 2019
July 25, 2019Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...Innate Pharma announces publication of IPH4102 Phase I clinical trial results for CTCL in the Lancet Oncology
June 26, 2019Data to date demonstrate high activity and favorable safety profile in Sézary syndrome, an aggressive form of cutaneous T-cell lymphoma (CTCL) International IPH4102 TELLOMAK Phase II clinical trial...Innate Pharma to host key opinion leader call on IPH4102 “TELLOMAK” clinical trial design and rationale
June 20, 2019Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), today announced that it will host a key opinion leader (KOL) call focused on the topic of IPH4102 “TELLOMAK” clinical trial...Innate Pharma announces intention to conduct a registered offering in the United States
June 12, 2019Innate Pharma, S.A. (Euronext Paris: IPH) today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares (“ADSs”), in the...Innate Pharma to present IPH4102 “TELLOMAK” clinical trial design and preclinical PTCL data at the 2019 ICML
June 12, 2019Multicohort, multi-center, international Phase II study to evaluate the efficacy and safety of IPH4102 in patients with advanced T-cell lymphoma is ongoing Sézary syndrome cohort of the TELLOMAK...Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
June 6, 2019TELLOMAK is a Phase II study to evaluate the efficacy of IPH4102 in different subtypes of T-cell lymphoma The TELLOMAK trial design and preclinical data in PTCL will be presented at the International...
